Recent Updates
Recently added Catalysts
ETON Positive Sentiment

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Wednesday, May 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Eton Pharmaceuticals, Inc., an innovative company specializing in treatments for rare diseases, will present at the Citizens JMP Life Sciences Conference on May 13, 2024. The presentation will be led by CEO Sean Brynjelsen and CFO James Gruber. Eton currently has several commercial products and additional candidates in late-stage development, signaling its commitment to advancing healthcare for rare conditions.
Price reaction · baseline $3.5 (2024-04-30 close) · hit after-hours · clean, no other ETON news in the window
day 0 close
+5.1%
day 1 · peak
+7.1%
day 3
+7.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals is presenting at a significant industry conference.
  • The company's focus on rare diseases highlights its innovative approach.
  • Eton has multiple commercial products and late-stage candidates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+89%
120-day peak, hindsight
Typical move
14.8%
average across 5 past catalysts

Full Press Release Details

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:
Date: Monday, May 13, 2024
Time: 10:00am ET
Webcast: Click Here
To schedule a 1x1 meeting with the Company, please contact your Citizens JMP institutional sales representative.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.

Frequently Asked Questions

When will Eton Pharmaceuticals present at the conference?

Eton Pharmaceuticals will present on May 13, 2024.

Who will represent Eton Pharmaceuticals at the conference?

Sean Brynjelsen and James Gruber will represent Eton at the conference.

What products does Eton currently offer?

Eton offers five rare disease products, including ALKINDI SPRINKLE® and PKU GOLIKE®.

How many product candidates are in late-stage development at Eton?

Eton has three product candidates in late-stage development.

Where can I find more information about Eton Pharmaceuticals?

More information is available on Eton's website at www.etonpharma.com.

ShareAdd on Google
Tags: ETON Viatris Investor Conferences Healthcare rare diseases JMP Conference biopharma innovative treatments
Last updated: May 1, 2024

Biotech snapshot

Cash runway
$27M liquidity · $0M/mo burn
Low dilution risk

Catalyst track record

+89%
best trade around ETON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ETON.

See every catalyst's timing & PoA →